Zevra Therapeutics, Inc. (ZVRA)
(Real Time Quote from BATS)
$4.73 USD
+0.06 (1.29%)
Updated May 31, 2024 12:56 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Zevra Therapeutics, Inc. [ZVRA]
Reports for Purchase
Showing records 1 - 20 ( 28 total )
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
1Q24: Commercial Pipeline Progressing Well, Comfortably Funded Into 2026
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
4Q EPS Optics Not Material; Looking Forward to Transformational 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
4Q23: KP1077 Phase 2 Win, Arimoclomol PDUFA Set, Another AZSTARYS Milestone
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol PDUFA Extension Not a Material Delay; Perhaps Even Bolsters View on Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol PDUFA Date Pushed to Sept 21, 2024, Not Material In Our View
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Updating Our Model For the New Zevra; Target to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol NDA Resubmitted On Time, Expecting Late 2Q24 PDUFA Date
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
3Q23: Arimoclomol NDA ACER Acquired By YE23, IH Data 1H24, Well Funded; PT to $22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Data Presented at CNS Annual Meeting Show Long-Term Arimoclomol Benefit
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Interim Phase 2 KP1077 Results in IH Show Safety, Final Results in 1H24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Presents Full Phase 1 CV Safety PK Data for KP1077 Versus Ritalin
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
To Acquire ACER By YE23, Making Good on Orphan Drug Company Promise; $25 PT
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J